



A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

## Washington State Transactions by Industry



### Deals by sector



\*As of February 1<sup>st</sup>, 2017



Highlights

## January Highlights

- *Transactions* in January 2017 were worth ~5x as much as transactions in January 2016 despite similar numbers of deals (9 vs 8 respectively)
- *PVP Biologics*, a University of Washington spinout, inks \$35 million dollar deal with Takeda Pharmaceuticals
- *Health 123*, launched in 2011, was acquired by Samepage Health for an undisclosed amount
- *The Bill and Melinda Gates Foundation* awarded UW \$279M to be distributed over 10 years to study population health across the world
- *Biotechnology companies* comprised 2 of the 9 participants selected for Seattle Techstars Class of 2017: CuePath Innovation and Silene Biotech. Demo day is April 19<sup>th</sup>



## SBIR and STTR Funding Overview

The following information was compiled from the [NIH SBIR/STTR Award Data Table #216](#). Massachusetts and California were selected because of their robust life science sectors. Michigan was selected because of its active state SBIR/STTR Program and Oregon was selected for a PNW reference point.



While WA receives significantly less SBIR funding relative to CA or MA, we have seen a 1.95X increase in SBIR funding since 2012. Similarly, of the states analyzed, WA reported the largest increase in STTR funding since 2012, 2.63X, and is the only state to receive increased STTR funding from 2015 to 2016.

## Distribution of SBIR Funding



Washington is 1 of the 10 states accounting for 70% of *all* 2016 SBIR Funding

Washington's average 4 year success rate for SBIR Funding is 18%, slightly better than the national success rate of 17.6%

**Washington Life Science Transactions 2017**

<b>Date</b>	<b>Company</b>	<b>Type</b>	<b>Amount</b>
01/01/17	Adaptive Biotechnologies	Grant/SBIR	\$519,759
01/01/17	Group Health Cooperative	Grant	\$249,179
01/01/17	Lumithera, Inc	Grant/SBIR	\$140,000
01/02/17	PAI Life Science	Grant/SBIR	\$1,380,664
01/05/17	Aqueduct Critical Care, Inc	Debt	\$2,010,000
01/05/17	PVP Biologics	Partnership	\$35,000,000
01/12/17	OtoNexus Medical Technologies	Equity	\$7,849,073
01/13/17	Vicis, Inc	Debt	\$4,100,000
01/25/17	KenSci	Series A	\$8,500,000
<b>2017 Running Total</b>			<b>\$59,748,675</b>

**Don't see a transaction listed?**

**Contact Kayla Young at**

[kayla@lifesciencewa.org](mailto:kayla@lifesciencewa.org)

## Washington Life Science Transactions 2016

Date	Company	Type	Amount	Date	Company	Type	Amount
01/07/16	NanoString Technologies	Unknown	\$22,000,000	06/13/16	Alpine Immune Sciences	Equity	\$48,000,000
01/11/16	Spiral Genetics	Unknown	\$50,000	06/20/16	Kineta	Debt	\$1,752,688
01/12/16	Blaze Bioscience	Debt	\$991,000	06/22/16	Marina Biotech	Debt	\$300,000
01/14/16	Stemgenics	Equity	\$930,000	06/24/16	TwinStrand Biosciences	Debt	\$1,938,964
01/20/16	Vicis	Seed	\$8,000,000	07/05/16	Revalerio Corp	Equity	\$13,999,912
01/25/16	Clario Medical Imaging	Equity	\$185,000	07/14/16	Magnolia Medical Technologies	Series B	\$13,757,109
02/02/16	Oricula Therapeutics	Grant	\$2,060,000	07/19/16	Joylux	Equity	\$2,000,000
02/02/16	ID Genomics	Equity	\$50,000	07/26/16	Just Biotherapeutics	Series A	\$14,000,000
02/11/16	M3 Biotechnology	Equity	\$10,000,000	08/04/16	98point6	Equity	\$11,000,000
02/11/16	Spiral Genetics	Unknown	\$50,000	08/05/16	Mirabilis Medica	Debt	\$5,000,000
02/16/16	Physio-Control	Acquisition	\$1,280,000,000	08/09/16	CSATS	Equity	\$3,283,516
02/16/16	KPI Therapeutics	Debt	\$50,500	08/09/16	SpringStar	Grant	\$1,500,000
02/17/16	GlycoStasis	Acquisition	undisclosed	08/10/16	Ave Maria Biotechnology	Equity	\$100,000
02/23/16	Cytodyn	Equity	\$30,574,665	08/17/16	Kineta IO, LLC	Equity	\$238,422
02/24/16	Ave Maria Biotechnology	Equity	\$40,000	08/17/16	Kineta One, LLC	Debt	\$125,000
02/29/16	VitalWare	Series A	undisclosed	08/17/16	Vie Diagnostics	Grant	\$225,000
02/29/16	NanoString Technologies	Partnership	\$24,000,000	08/19/16	Nexgenia	Equity	\$1,859,887
03/03/16	LabConnect	Venture Equity	\$4,000,000	08/23/16	Benaroya Research Institute	Grant	\$8,000,000
03/11/16	Allen Institute for Brain Science	Contract	\$18,700,000	08/24/16	Briotech	Equity	\$250,000
03/16/16	Ave Maria Biotechnology	Equity	\$350,000	08/29/16	Impel Neuropharma	Debt	\$1,090,000
03/17/16	Act X	Unknown	\$308,810	08/29/16	Navisonics	Debt	\$335,000
03/22/16	Seattle Children's Research Institute	Grant	\$1,000,000	08/30/16	KinDex Pharmaceuticals	Debt	\$327,274
03/22/16	Breast Microseed	Debt	\$100,000	09/16/16	Sound Pharmaceuticals	Debt	\$3,800,000
03/23/16	Frazier Healthcare Partners	Fund	\$525,000,000	09/16/16	Cocrystal Discovery	Equity	\$4,008,201
03/23/16	University of Washington	Grant	\$250,000	09/20/16	Immune Design	Public Offering	\$30,300,000
03/24/16	The Paul G. Allen Frontiers Group	Fund	\$100,000,000	09/26/16	Ario	Equity	\$1,035,000
04/06/16	Cyrus Biotechnology	Debt	\$535,000	09/28/16	Verda Bio	Equity	\$545,000
04/06/16	2Morrow	Debt	\$325,000	09/29/16	PotaVida	Equity	\$275,000
04/07/16	Medstreaming LLC	Equity	\$12,200,000	10/06/16	Infectious Disease Research Institute	Grant	\$491,000
04/07/16	Prevensio, Inc	Debt	\$675,000	10/13/16	Feminina Group	Debt	\$77,500
04/08/16	Medstreaming LLC	Equity	\$2,500,000	10/13/16	Vicis	Debt	\$3,955,000
04/12/16	Silverback Therapeutics	Equity	\$10,000,000	10/18/16	Impel Neuropharma	Debt	\$80,000
04/14/16	Vicis	Series A	\$4,000,000	10/18/16	Sightlight Surgical	Series A	\$10,000,000
04/18/16	Juno Therapeutics	Partnership	\$50,000,000	10/18/16	Infectious Disease Research Institute	Partnership	\$15,000,000
04/23/16	ID Genomics	Grant	\$3,000,000	10/18/16	Deep Cell Industries	Equity	\$25,000
04/27/16	Cardiac Insight	Debt	\$2,505,524	11/01/16	Immusoft Corp	Series A	\$2,739,999
04/29/16	Ave Maria Biotechnology	Equity	\$2,200,000	11/07/16	Act X	Equity	\$1,900,646
05/05/16	Kineta	Award	\$7,200,000	11/16/16	Cyrus Biotechnology	Equity	\$490,000
05/10/16	Aqueduct Critical Care	Equity	\$3,067,177	11/18/16	Invio, Inc	Angel	\$160,000
05/10/16	Spiral Genetics	Unknown	\$50,000	12/01/16	Washington State University	Grant	\$50,000
05/11/16	Cytodyn	Equity	\$4,301,500	12/01/16	Impel Neuropharma	Series C	\$22,297,064
05/11/16	Mental Health Data Services	Equity	\$333,333	12/05/16	Nohla Therapeutics	Series A	\$11,999,999
05/13/16	Ave Maria Biotechnology	Equity	\$50,000	12/05/16	KPI Therapeutics	Equity	\$18,000
05/17/16	PhaseRx	IPO	\$18,500,000	12/06/16	Cardiac Insight	Series C	\$1,000,000
05/20/16	Haverhill Genetics	Debt	\$125,000	12/08/16	ApoGen Biotechnologies, Inc	Series A	\$3,815,892
05/24/16	Vicis	Equity	\$6,000,000	12/08/16	Integrated Diagnostics	Equity	\$6,099,999
05/25/16	Kineta Three, LLC	Equity	\$760,778	12/13/16	Ave Maria Biotechnology	Equity	\$225,000
05/26/16	Litesprite	Debt	\$50,000	12/20/16	Briotech	Equity	\$100,000
05/31/16	Kineta Two, LLC	Equity	\$67,275	12/21/16	C3J Therapeutics	Equity	\$18,999,999
06/02/16	Mirabilis Medica	Debt	\$2,232,833	12/28/16	Valant Medical Solutions	Equity	\$7,500,000
06/09/16	Ave Maria Biotechnology	Equity	\$100,000				
06/09/16	Cadence Biomedical	Debt	\$80,000				
				<b>2016 Total</b>			<b>\$2,435,649,466</b>

Don't see a transaction listed?

Contact Kayla Young at

[kayla@lifesciencewa.org](mailto:kayla@lifesciencewa.org)

This report is prepared by Wendy Yang, PhD, and Kayla Young, PhD. Questions or comments? Contact [kayla@lifesciencewa.org](mailto:kayla@lifesciencewa.org).

\*\*The data in this report are compiled from publicly disclosed information and is not independently verified by Life Science Washington.